Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).
Rene-Olivier Casasnovas
Consultant or Advisory Role - Roche; Spectrum Pharmaceuticals
Honoraria - Roche
Research Funding - Roche
Loic Ysebaert
Honoraria - Roche
Catherine Thieblemont
Honoraria - Roche
Bertrand Coiffier
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Serge Bologna
No relevant relationships to disclose
Gerard Lepeu
No relevant relationships to disclose
Alain Delmer
No relevant relationships to disclose
Isabelle Plantier
No relevant relationships to disclose
Jean Gabarre
No relevant relationships to disclose
Marc Andre
No relevant relationships to disclose
Delphine Senecal
No relevant relationships to disclose
Christophe Fruchart
No relevant relationships to disclose
Michel Meignan
No relevant relationships to disclose
Alina Berriolo-Riedinger
No relevant relationships to disclose
Stephane Bardet
No relevant relationships to disclose
Thierry Jo Molina
No relevant relationships to disclose
Jean-Philippe Jais
No relevant relationships to disclose
Corinne Haioun
Consultant or Advisory Role - Roche/Genentech; Spectrum Pharmaceuticals
Honoraria - Roche/Genentech
Herve Tilly
Consultant or Advisory Role - Roche/Genentech; Spectrum Pharmaceuticals
Franck Morschhauser
Consultant or Advisory Role - Roche/Genentech; Spectrum Pharmaceuticals